Empirical therapy advisor
Before culture results are back: how likely is each antibiotic to cover the pathogen of a patient like this one, in this ward, given the last 12 months of results and today's alerts.
Based on 644 first isolates · URO · Cystitis (lower UTI) · 2024-06-23 → 2025-06-22
UrologyNarrowest option reaching 80 % coverage, no active warning
nitrofurantoin 84 % (81 %–86 %)
No tissue or blood levels: cystitis only.
Not covered: Klebsiella pneumoniae (6 %), Proteus mirabilis (5 %), Pseudomonas aeruginosa (5 %)
AntibioticCoverage, 12 months (95 % CI)12 mo4 wk
ciprofloxacin CIP
trend · Escherichia coli ⚠ Escherichia coli: 49 % resistant in the last 4 weeks (baseline 10 %)
75 %
52 %
n = 60
ceftriaxone CRO
trend · Escherichia coli ⚠ Active ESBL cluster (17 cases)
⚠ Escherichia coli: 46 % resistant in the last 4 weeks (baseline 4 %)
73 %
53 %
n = 60
cefuroxime CXM
trend · Escherichia coli ⚠ Active ESBL cluster (17 cases)
⚠ Escherichia coli: 46 % resistant in the last 4 weeks (baseline 13 %)
67 %
52 %
n = 60
⚠ Escherichia coli: 51 % resistant in the last 4 weeks (baseline 20 %)
67 %
52 %
n = 60
Most likely organisms for this profile
Escherichia coli
58 %
Klebsiella pneumoniae
11 %
Enterococcus faecalis
10 %
Proteus mirabilis
5 %
Pseudomonas aeruginosa
5 %
Staphylococcus saprophyticus
3 %
Decision support only: coverage is the share of first isolates from similar patients that were susceptible (an organism not tested for a drug counts as not covered). It does not replace local treatment guidelines, allergy and severity assessment, or clinical judgement. The black tick on each bar is the coverage target; the bracket is the 95 % confidence interval.